Skip to Content
UW Health SMPH
American Family Children's Hospital
DONATE Donate
SHARE TEXT

The mission of the UW Carbone Cancer Center (UWCCC) Experimental Therapeutics (XT) Scientific Program is to discover new targets and therapeutic agents, translate and advance these discoveries through clinical trials and use information and resources from these clinical trials to understand mechanisms of response and resistance that will inform XT members of potentially superior therapeutic approaches.

 

Program Leaders

F. Michael Hoffmann, PhDDoug McNeel, MD, PhD

 

The XT Program members conduct their clinical research utilizing the multidisciplinary, translational infrastructure of Disease Oriented Working Groups (DOWGs) and the Cancer Therapy Discovery and Development (CTD2) Clinical Research Group (CRG) which are embedded within the Program.

 

The DOWGs/CRGs consist of teams of clinicians (medical oncologists, cancer surgeons, radiation oncologists, medical specialists and pathologists), translational researchers, laboratory scientists, clinical trialists, biostatisticians and clinical/regulatory research staff with expertise in specific cancer types or specific research areas.  DOWGs/CRGs are the primary structures by which we accomplish advancing promising agents from early phase clinical trials through later stage clinical trials, and each DOWG is essentially a functional clinical research unit with disease-specific cancer expertise.   

 

While many members of each DOWG/CRG are members of the XT Program, the make-up of the DOWGs/CRGs also includes members from all other UWCCC Scientific Programs. Therefore the structure of the DOWGs/CRGs greatly facilitates inter-programmatic collaboration and interaction among different Programs along clinical disease lines. By sharing developments in the laboratory and clinical worlds, ongoing collaborations are strengthened, new hypotheses are generated and better studies are designed.